Synthomer Sells Acrylate Business to Mutares, Eyes Speciality Chemicals

🔥 Main Takeaway

Synthomer is strategically offloading its capital-intensive acrylate monomers business to Mutares. This signals a sharp pivot towards higher-margin speciality chemicals and a leaner operational model for the company.

📌 What Happened?

Global polymer supplier Synthomer confirmed the divestment of its Czech-based acrylate monomers business, Synthomer a.s., to Mutares, a Munich-based private equity firm. This unit employs around 300 staff at its Sokolov site and is a key supplier to the European market.

The decision stems from a strategic review initiated in October 2022, which identified the business as non-core due to its highly cyclical and capital-intensive nature. CEO Michael Willome emphasized this move is crucial for simplifying operations and sharpening the focus on speciality chemicals.

Financially, the divested business reported EUR 68 million in external sales in 2025, incurring an adjusted EBITDA loss of EUR 10 million. Although trading conditions improved to break-even in early 2026, the unit still required approximately EUR 5 million annually in capital expenditure.

The transaction, expected to close by the end of Q3 2026, involves no initial payment at closing. Instead, it includes a cash generation sharing arrangement of up to EUR 12 million over three years, alongside EUR 5 million in cash for the divested company’s working capital needs.

💰 Why It Matters

For Synthomer, this move streamlines its portfolio, shedding a low-margin, high-capital-intensity segment. This allows the company to reallocate resources towards more profitable and growth-oriented speciality chemicals, potentially boosting investor confidence.

The transaction structure, featuring no upfront payment and a cash-sharing model, highlights a focus on future performance and operational efficiency. This could be a smart way to offload a challenging asset without immediate cash strain while still benefiting from its potential turnaround.

For Mutares, acquiring a business that previously lost EUR 10 million EBITDA and requires EUR 5 million in annual CapEx signals a high-risk, high-reward turnaround play. Their expertise in distressed assets suggests they see significant potential for operational improvements and value creation within the acquired unit.

👀 What to Watch Next

Investors should monitor Synthomer’s subsequent moves in the speciality chemicals sector, looking for new investments or strategic acquisitions that reinforce its stated focus. The overall effectiveness of its streamlined portfolio will be a key indicator of success.

Keep an eye on Mutares’ strategy for Synthomer a.s. after the Q3 2026 closing. Any swift operational changes or market repositioning efforts will indicate their path to profitability and how they plan to unlock the up to EUR 12 million cash generation sharing.

The broader chemical market’s recovery will also influence the success of this divestment. Improved trading conditions could accelerate the turnaround for the divested business, ultimately benefiting both parties involved through the cash-sharing agreement.